With Hidden Dividend Stocks Plus he scours the world's markets to find solid income opportunities with dividend yields ranging from 5% to 10% or more, backed by strong earnings. Features include: a portfolio with up to 40 holdings at a time including links to associated articles, a dividend calendar, weekly research articles, exclusive ideas, and trade alerts. Learn More . Robert Hauver, MBA, aka "Double Dividend Stocks" was VP of Finance for an industry-leading corporation for 18 years and has been investi ...

This Dividend Represents an Increase of Approximately 4.2% as Compared to Same Second Quarter of Fiscal 2024 NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE:SAR) ("Saratoga Investment" or "the Company"), a business development company, today announced that its Board of Directors has declared a quarterly dividend of $0.74 per share for the fiscal second quarter ending August 31, 2024, which represents a 4.2% increase as compared to the $0.71 per share distributed in the second qua ...

Financial Data and Key Metrics Changes - Saratoga's adjusted net investment income (NII) per share increased by 12% compared to the previous quarter, reflecting a 19% increase in recurring net interest margin driven by a 9% rise in average assets under management [21][28] - The company's total expenses increased from $2.3 million to $2.9 million compared to last year, representing 1.0% of average total assets on an annualized basis, up from 0.8% last year [29] - The net asset value (NAV) was $367.9 million, a decrease of $2.3 million from the last quarter but an increase of $30.4 million from the same quarter last year [30] Business Line Data and Key Metrics Changes - Originations this quarter totaled $39 million, while repayments and amortization amounted to $76 million, leading to a quarter-end cash position of $93.3 million [24] - The credit quality remained high, with 98.3% of credits rated in the highest category, and only 1.6% of fair value in non-accrual status [25] Market Data and Key Metrics Changes - The overall M&A activity for private equity-backed deals is at record lows, impacting new investment opportunities [3][4] - The company noted that competition on pricing is increasing due to the capital sitting on the sidelines and low new deal activity [4][47] Company Strategy and Development Direction - The company is focusing on the lower end of the middle market, which is viewed as a favorable position for credit quality and deal activity [6][47] - Management is actively implementing changes to capital structure and business plans to enhance recovery value [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deploy capital effectively despite the current low deal activity, emphasizing the importance of maintaining high underwriting standards [7][60] - The management team is focused on supporting existing portfolio companies and managing a few challenged credits, with a strong emphasis on maintaining balance sheet strength and liquidity [38][62] Other Important Information - The company has a significant amount of dry powder available, totaling $299 million, which includes cash and undrawn credit facilities [31] - The annualized dividend of $0.74 per share reflects a 13.1% dividend yield, with the company over-earning its dividend by $0.31 this quarter [26][72] Q&A Session Summary Question: Can you provide commentary on the investing environment and repayment activity? - Management noted that while M&A activity is low, there are still opportunities to support existing portfolio companies, and repayment activity may pick up due to aggressive pricing from lenders [3][4] Question: How is the cash position and undistributed income being managed? - The company mentioned a growing cash position and is evaluating the undistributed income in light of potential future investments [8][9] Question: What is the nature of the follow-on investments made this quarter? - Most follow-on investments were for tuck-in acquisitions in existing platforms, reflecting a strategy that has historically worked well [96] Question: Can you elaborate on the non-accrual investments and their status? - Management confirmed that three investments remain on non-accrual, with ongoing efforts to recover capital from these investments [62][64] Question: How does the company view the competitive landscape in the current market? - While some larger private credit platforms are moving down market, the company has not seen significant competition affecting its operations [14][16]

Saratoga Investment Corp. Fiscal First Quarter 2025 Shareholder Presentation July 10, 2024 Steady Long-Term Growth and Performance in Q1 2025 Fiscal First Quarter 2025 Highlights: • 98.3% of loan investments with highest internal rating and three non-accruals (1.6% of fair value / 4.8% of cost) • Remaining total Pepper Palace and Zollege fair value as of quarter-end is $4.4m • Fair value of $1.096 billion is 2.4% below total cost of portfolio, with core non-CLO BDC portfolio, excluding Zollege and Pepper Pa ...

Saratoga Investment (SAR) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.25%. A quarter ago, it was expected that this business development company would post earnings of $0.96 per share when it actually produced earnings of $0.94, delivering a surprise of -2.08%. Over the last fo ...

For the three months ended and as of February 29, 2024 NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE:SAR) ("Saratoga Investment" or "the Company"), a business development company ("BDC"), today announced financial results for its 2025 fiscal first quarter, with Net Investment Income ("NII") per share of $1.05 versus $1.35 last year and $0.94 for last year's fourth quarter, and adjusted NII per share of $1.05 versus $1.08 last year and $0.94 for last year's fourth quarter. The C ...

Saratoga Investment's annualized first quarter dividend of $0.74 per share and adjusted net investment income of $1.05 per share imply a 13.1% dividend yield and 18.6% earnings yield based on its recent stock price of $22.59 per share on July 8, 2024. This substantial overearning of the dividend by 31c this quarter, or $1.24 annualized per share, amply supports the increased level of dividends, increases Net Asset Value ("NAV"), supports increased portfolio growth and provides a cushion against adverse even ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE:SAR) ("Saratoga Investment" or "the Company"), a business development company ("BDC"), today announced financial results for its 2025 fiscal first quarter, with Net Investment Income ("NII") per share of $1.05 versus $1.35 last year and $0.94 for last year's fourth quarter, and adjusted NII per share of $1.05 versus $1.08 last year and $0.94 for last year's fourth quarter. Saratoga Investment's annualized first quarter dividend of $ ...

1M USD TERM SOFR - The 1 month USD TERM SOFR rate as of February 29, 2024 was 5.32%. 3M USD TERM SOFR - The 3 month USD TERM SOFR rate as of February 29, 2024 was 5.33%. 6M USD TERM SOFR - The 6 month USD TERM SOFR rate as of February 29, 2024 was 5.27%. PIK - Payment-in-Kind (see Note 2 to the consolidated financial statements). Note 1. Organization The Company is externally managed and advised by the investment adviser, Saratoga Investment Advisors, LLC (the "Manager" or "Saratoga Investment Advisors"), p ...

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) Phase 2 trials to more rapidly pr ...